vTv Therapeutics Q1 Revenue Reaches $36.84M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $36.84M, consensus $10M. "We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes," said Paul Sekhri, chairman, president, and CEO of vTv Therapeutics. "Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTVT
Wall Street analysts forecast VTVT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.000
Low
40.00
Averages
51.33
High
67.00
Current: 33.000
Low
40.00
Averages
51.33
High
67.00
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
vTv Therapeutics Q1 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q1 GAAP EPS of $1.65, beating expectations by $1.21, which highlights a significant improvement in the company's profitability and reflects robust performance in its core business.
- Substantial Revenue Growth: The company achieved revenues of $36.84 million in Q1, exceeding market expectations by $26.84 million, indicating strong sales and market demand for its products, further solidifying its position in the biopharmaceutical sector.
- Future Catalyst: The Phase 3 CATT1 readout for Cadisegliatin is poised to be a crucial catalyst for the company, expected to drive stock price increases and attract more investor attention, thereby enhancing market confidence.
- Positive Quant Ratings: Seeking Alpha's quant rating on vTv Therapeutics shows a positive trend, indicating analysts' optimism regarding the company's future growth potential, which may further encourage investor buying interest.
See More
Wall Street Analysts Adjust NIO Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on NIO stock, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Overview of Rating Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing expectations from analysts regarding NIO's future performance, which may lead to stock price volatility.
- Market Reaction Potential: Changes in analyst ratings could attract investor attention, potentially impacting NIO's market performance, especially in the currently competitive electric vehicle sector.
- Investor Decision Impact: As analysts revise their views on NIO, investors may reassess their investment strategies, thereby affecting NIO's stock price trajectory and overall market confidence.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying perspectives on their future prospects, which could influence investor decisions.
- Overview of Updates: The rating changes include upgrades, downgrades, and initiations, showcasing analysts' keen response to market dynamics, potentially leading to stock price volatility.
- Investor Focus: Investors considering buying EVCM stock should pay attention to the latest insights from analysts, as these could impact their investment strategies and market confidence.
- Market Dynamics Impact: Changes in analyst ratings not only affect individual stock performance but may also influence overall market sentiment, prompting investors to closely monitor these developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these firms.
- Market Dynamics Observation: While specific company names are not disclosed, changes in analyst ratings typically influence investor confidence, thereby directly impacting the market performance of the related stocks.
- Investor Decision Reference: Investors considering buying FPI stock can refer to these analyst rating changes to make more informed investment decisions, although specific recommendations are not provided.
- Transparent Information Source: Benzinga's market news and data aim to provide investors with comprehensive insights into analyst rating changes, helping them better understand market dynamics.
See More
vTv Therapeutics Reports 2025 Financials and Pipeline Progress
- Financial Performance: vTv Therapeutics reported a net loss of $7.1 million in Q4 2025, translating to a basic loss of $0.58 per share, which is an increase from the $3.6 million loss in the same quarter of 2024, highlighting the pressure from rising R&D expenditures.
- R&D Progress: The company initiated the Phase 3 CATT1 trial for Cadisegliatin in 2025, and despite initial slow patient recruitment, the acceleration in enrollment momentum was achieved by increasing participating sites and enhancing patient engagement, with completion expected by Q3 2026.
- Financial Position: vTv ended 2025 with $88.9 million in cash and cash equivalents, bolstered by an $80 million private placement completed in September 2025, with management indicating that this funding will support operations well past the anticipated topline readout of the Phase 3 trial.
- Strategic Partnership: The company received a $20 million milestone payment from Newsoara Biopharma under an amended licensing agreement, which includes up to $50 million in development milestones and $65 million in sales milestones, indicating potential expansion of Cadisegliatin's reach into type 2 diabetes.
See More
vTv Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.50, indicating improved financial management and increased market confidence in the company's prospects.
- Significant Cash Reserves Growth: As of December 31, 2025, the company's cash position rose to $88.9 million from $36.7 million in 2024, primarily due to proceeds from the private placement financing announced on September 2, 2025, enhancing the company's financial flexibility.
- Far-Reaching Financing Impact: The successful private placement not only improved cash flow but also provided funding for future R&D and market expansion, expected to accelerate the clinical trial process for Cadisegliatin.
- Future Catalysts: With the upcoming readout of Cadisegliatin's Phase 3 CATT1 trial results, vTv Therapeutics is poised for new market catalysts that could further drive stock price appreciation and attract more investor interest.
See More
vTv Therapeutics Q1 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q1 GAAP EPS of $1.65, beating expectations by $1.21, which highlights a significant improvement in the company's profitability and reflects robust performance in its core business.
- Substantial Revenue Growth: The company achieved revenues of $36.84 million in Q1, exceeding market expectations by $26.84 million, indicating strong sales and market demand for its products, further solidifying its position in the biopharmaceutical sector.
- Future Catalyst: The Phase 3 CATT1 readout for Cadisegliatin is poised to be a crucial catalyst for the company, expected to drive stock price increases and attract more investor attention, thereby enhancing market confidence.
- Positive Quant Ratings: Seeking Alpha's quant rating on vTv Therapeutics shows a positive trend, indicating analysts' optimism regarding the company's future growth potential, which may further encourage investor buying interest.
See More
Wall Street Analysts Adjust NIO Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on NIO stock, reflecting varying market perspectives that could influence investor decisions and market sentiment.
- Overview of Rating Updates: The adjustments include upgrades, downgrades, and initiations, indicating differing expectations from analysts regarding NIO's future performance, which may lead to stock price volatility.
- Market Reaction Potential: Changes in analyst ratings could attract investor attention, potentially impacting NIO's market performance, especially in the currently competitive electric vehicle sector.
- Investor Decision Impact: As analysts revise their views on NIO, investors may reassess their investment strategies, thereby affecting NIO's stock price trajectory and overall market confidence.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying perspectives on their future prospects, which could influence investor decisions.
- Overview of Updates: The rating changes include upgrades, downgrades, and initiations, showcasing analysts' keen response to market dynamics, potentially leading to stock price volatility.
- Investor Focus: Investors considering buying EVCM stock should pay attention to the latest insights from analysts, as these could impact their investment strategies and market confidence.
- Market Dynamics Impact: Changes in analyst ratings not only affect individual stock performance but may also influence overall market sentiment, prompting investors to closely monitor these developments.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these firms.
- Market Dynamics Observation: While specific company names are not disclosed, changes in analyst ratings typically influence investor confidence, thereby directly impacting the market performance of the related stocks.
- Investor Decision Reference: Investors considering buying FPI stock can refer to these analyst rating changes to make more informed investment decisions, although specific recommendations are not provided.
- Transparent Information Source: Benzinga's market news and data aim to provide investors with comprehensive insights into analyst rating changes, helping them better understand market dynamics.
See More
vTv Therapeutics Reports 2025 Financials and Pipeline Progress
- Financial Performance: vTv Therapeutics reported a net loss of $7.1 million in Q4 2025, translating to a basic loss of $0.58 per share, which is an increase from the $3.6 million loss in the same quarter of 2024, highlighting the pressure from rising R&D expenditures.
- R&D Progress: The company initiated the Phase 3 CATT1 trial for Cadisegliatin in 2025, and despite initial slow patient recruitment, the acceleration in enrollment momentum was achieved by increasing participating sites and enhancing patient engagement, with completion expected by Q3 2026.
- Financial Position: vTv ended 2025 with $88.9 million in cash and cash equivalents, bolstered by an $80 million private placement completed in September 2025, with management indicating that this funding will support operations well past the anticipated topline readout of the Phase 3 trial.
- Strategic Partnership: The company received a $20 million milestone payment from Newsoara Biopharma under an amended licensing agreement, which includes up to $50 million in development milestones and $65 million in sales milestones, indicating potential expansion of Cadisegliatin's reach into type 2 diabetes.
See More
vTv Therapeutics Q4 Earnings Exceed Expectations
- Strong Earnings Report: vTv Therapeutics reported a Q4 GAAP EPS of -$0.58, beating expectations by $0.50, indicating improved financial management and increased market confidence in the company's prospects.
- Significant Cash Reserves Growth: As of December 31, 2025, the company's cash position rose to $88.9 million from $36.7 million in 2024, primarily due to proceeds from the private placement financing announced on September 2, 2025, enhancing the company's financial flexibility.
- Far-Reaching Financing Impact: The successful private placement not only improved cash flow but also provided funding for future R&D and market expansion, expected to accelerate the clinical trial process for Cadisegliatin.
- Future Catalysts: With the upcoming readout of Cadisegliatin's Phase 3 CATT1 trial results, vTv Therapeutics is poised for new market catalysts that could further drive stock price appreciation and attract more investor interest.
See More
